The effect of electronegativity and angiotensin-converting enzyme inhibition on the kinin-forming capacity of polyacrylonitrile dialysis membranes

被引:40
作者
Desormeaux, Anik [1 ]
Moreau, Marie Eve [1 ]
Lepage, Yves [2 ]
Chanard, Jacques [3 ,4 ]
Adam, Albert [1 ]
机构
[1] Univ Montreal, Fac Pharm, Montreal, PQ H3T 1J4, Canada
[2] Univ Montreal, Dept Math & Stat, Fac Arts & Sci, Montreal, PQ H3C 3J7, Canada
[3] Ctr Hosp & Univ, ARPDD, Nephrol Hemodial Transplantat Serv, Reims, France
[4] CNRS, FRE 2534, Reims, France
关键词
haemodialysis membrane; biocompatibility; electroactive polymer; hypersensitivity;
D O I
10.1016/j.biomaterials.2007.11.019
中图分类号
R318 [生物医学工程];
学科分类号
0831 [生物医学工程];
摘要
The combination of negatively-charged membranes and angiotensin I-converting enzyme inhibitors (ACEi) evokes hypersensitivity reactions (HSR) during hemodialysis and bradykinin (BK)-related peptides have been hypothesized as being responsible for these complications. In this study, we tested the effects of neutralizing the membrane electronegativity (zeta potential) of polyacrylonitrile AN69 membranes by coating a polyethyleneimine layer (AN69-ST membranes) over the generation of kinins induced by blood contact with synthetic membranes. We used minidialyzers with AN69 or AN69-ST membranes in an ex vivo model of plasma and we showed that plasma dialysis with AN69 membranes led to significant BK and des-Arg(9)-BK release, which was potentiated by ACEi. This kinin formation was dramatically decreased by AN69-ST membranes, even in the presence of an ACEi, and kinin recovery in the dialysates was also significantly lower with these membranes. High molecular weight kininogen and factor XII detection by immunoblotting of the protein layer coating both membranes corroborated the results: binding of these proteins and contact system activation on AN69-ST membranes were reduced. This ex vivo experimental model applied to the plasma, dialysate and dialysis membrane could be used for the characterization of the kinin-forming capacity of any biomaterial potentially used in vivo in combination with drugs which modulate the pharmacological activity of kinins. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1139 / 1146
页数:8
相关论文
共 22 条
[1]
Adam A, 2004, Bull Mem Acad R Med Belg, V159, P307
[2]
ADAM A, 1985, CLIN CHEM, V31, P423
[3]
ADAM A, 2004, B MEM ACAD R MED BEL, V159, P314
[4]
BOMMER J, 1985, LANCET, V2, P1382
[5]
Chanard J, 1987, ASAIO Trans, V33, P551
[6]
New insights in dialysis membrane biocompatibility: relevance of adsorption properties and heparin binding [J].
Chanard, J ;
Lavaud, S ;
Randoux, C ;
Rieu, P .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (02) :252-257
[7]
Bradykinin and des-Arg9-bradykinin metabolic pathways and kinetics of activation of human plasma [J].
Cyr, M ;
Lepage, Y ;
Blais, C ;
Gervais, N ;
Cugno, M ;
Rouleau, JL ;
Adam, A .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2001, 281 (01) :H275-H283
[8]
Decarie A, 1996, PEPTIDES, V17, P1009
[9]
DEVELOPMENT OF DIGOXIGENIN-LABELED PEPTIDE - APPLICATION TO CHEMILUMINOENZYME IMMUNOASSAY OF BRADYKININ IN INFLAMED TISSUES [J].
DECARIE, A ;
DRAPEAU, G ;
CLOSSET, J ;
COUTURE, R ;
ADAM, A .
PEPTIDES, 1994, 15 (03) :511-518
[10]
A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors [J].
Duan, QL ;
Nikpoor, B ;
Dubé, MP ;
Molinaro, G ;
Meijer, IA ;
Dion, P ;
Rochefort, D ;
Saint-Onge, J ;
Flury, L ;
Brown, NJ ;
Gainer, JV ;
Rouleau, JL ;
Agostoni, A ;
Cugno, M ;
Simon, P ;
Clavel, P ;
Potier, J ;
Wehbe, B ;
Benarbia, S ;
Marc-Aurèle, J ;
Chanard, J ;
Foroud, T ;
Adam, A ;
Rouleau, GA .
AMERICAN JOURNAL OF HUMAN GENETICS, 2005, 77 (04) :617-626